NCT06295796View on ClinicalTrials.gov

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Renal Impairment
Interventions
DRUG

MK-8527

Oral Capsule

Trial Locations (1)

60643

Research by Design ( Site 0001), Chicago

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06295796 - A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) | Biotech Hunter | Biotech Hunter